F4/80
AOM/DSS
Colitis
Colitis-Associated Cancer
Colorectal Cancer
Dclk1
Macrophages
Tuft Cells
Journal
Gastroenterology
ISSN: 1528-0012
Titre abrégé: Gastroenterology
Pays: United States
ID NLM: 0374630
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
15
05
2022
revised:
15
12
2022
accepted:
03
01
2023
pmc-release:
01
04
2024
pubmed:
13
1
2023
medline:
28
3
2023
entrez:
12
1
2023
Statut:
ppublish
Résumé
Colorectal cancer is a leading cause of cancer death, and a major risk factor is chronic inflammation. Despite the link between colitis and cancer, the mechanism by which inflammation leads to colorectal cancer is not well understood. To investigate whether different forms of inflammation pose the same risk of cancer, we compared several murine models of colitis (dextran sodium sulfate [DSS], 2,4,6-trinitrobenzene sulfonic acid, 4-ethoxylmethylene-2-phenyloxazol-5-one, Citrobacter rodentium, Fusobacterium nucleatum, and doxorubicin) with respect to their ability to lead to colonic tumorigenesis. We attempted to correlate the severity of colitis and inflammatory profile with the risk of tumorigenesis in both azoxymethane-dependent and Dclk1/APC DSS colitis reproducibly led to colonic tumors in both mouse models of colitis-associated cancer. In contrast, all other forms of colitis did not lead to cancer. When compared with the colitis not associated with tumorigenesis, DSS colitis was characterized by significantly increased CD11b We have identified CD11b
Sections du résumé
BACKGROUND & AIMS
Colorectal cancer is a leading cause of cancer death, and a major risk factor is chronic inflammation. Despite the link between colitis and cancer, the mechanism by which inflammation leads to colorectal cancer is not well understood.
METHODS
To investigate whether different forms of inflammation pose the same risk of cancer, we compared several murine models of colitis (dextran sodium sulfate [DSS], 2,4,6-trinitrobenzene sulfonic acid, 4-ethoxylmethylene-2-phenyloxazol-5-one, Citrobacter rodentium, Fusobacterium nucleatum, and doxorubicin) with respect to their ability to lead to colonic tumorigenesis. We attempted to correlate the severity of colitis and inflammatory profile with the risk of tumorigenesis in both azoxymethane-dependent and Dclk1/APC
RESULTS
DSS colitis reproducibly led to colonic tumors in both mouse models of colitis-associated cancer. In contrast, all other forms of colitis did not lead to cancer. When compared with the colitis not associated with tumorigenesis, DSS colitis was characterized by significantly increased CD11b
CONCLUSIONS
We have identified CD11b
Identifiants
pubmed: 36634827
pii: S0016-5085(23)00011-2
doi: 10.1053/j.gastro.2023.01.002
pmc: PMC10038892
mid: NIHMS1865714
pii:
doi:
Substances chimiques
Azoxymethane
MO0N1J0SEN
Dextran Sulfate
9042-14-2
Ly-6C antigen, mouse
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
593-609.e13Subventions
Organisme : NIDDK NIH HHS
ID : U01 DK085532
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK103155
Pays : United States
Organisme : NIDDK NIH HHS
ID : U24 DK085532
Pays : United States
Informations de copyright
Copyright © 2023 AGA Institute. Published by Elsevier Inc. All rights reserved.
Références
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
J Vis Exp. 2013 May 17;(75):e50210
pubmed: 23711911
Nat Rev Microbiol. 2014 Sep;12(9):612-23
pubmed: 25088150
Cancer Res. 2009 Oct 1;69(19):7884-92
pubmed: 19773434
Gut. 2020 Oct 29;:
pubmed: 33122176
Front Immunol. 2020 May 28;11:1052
pubmed: 32547556
Front Immunol. 2015 Jun 02;6:254
pubmed: 26082775
Nat Protoc. 2007;2(8):1998-2004
pubmed: 17703211
Cell. 2020 Apr 16;181(2):442-459.e29
pubmed: 32302573
J Exp Med. 1998 Nov 16;188(10):1929-39
pubmed: 9815270
Nat Protoc. 2017 Jul;12(7):1295-1309
pubmed: 28569761
Cytometry A. 2012 Apr;81(4):343-50
pubmed: 22213571
PLoS One. 2015 Apr 17;10(4):e0124080
pubmed: 25884830
Nat Biotechnol. 2019 Jul;37(7):773-782
pubmed: 31061481
Gastroenterology. 2005 Nov;129(5):1485-503
pubmed: 16285950
Gastroenterology. 2019 Apr;156(5):1467-1482
pubmed: 30550822
Cell Mol Gastroenterol Hepatol. 2015 Mar 1;1(2):154-170
pubmed: 26000334
J Exp Med. 2001 Mar 19;193(6):727-40
pubmed: 11257139
J Immunol Methods. 2015 Jun;421:61-72
pubmed: 25702536
Nat Commun. 2019 Jun 28;10(1):2892
pubmed: 31253778
Science. 2016 Sep 16;353(6305):1249-53
pubmed: 27634526
J Transl Med. 2012 Oct 03;10:205
pubmed: 23034130
N Engl J Med. 1990 Nov 1;323(18):1228-33
pubmed: 2215606
Immunity. 2017 May 16;46(5):764-766
pubmed: 28514680
PLoS One. 2013;8(1):e54302
pubmed: 23372702
Gut. 2001 Apr;48(4):526-35
pubmed: 11247898
Nat Protoc. 2007;2(3):541-6
pubmed: 17406617
Oncogene. 2008 Oct 6;27(45):5904-12
pubmed: 18836471
J Exp Med. 2009 May 11;206(5):1089-102
pubmed: 19398755
Cell Microbiol. 2005 Dec;7(12):1697-706
pubmed: 16309456
Sci Rep. 2016 Apr 06;6:23920
pubmed: 27050089
Am J Physiol Gastrointest Liver Physiol. 2018 Jan 1;314(1):G22-G31
pubmed: 29025731
EMBO Mol Med. 2020 Jan 9;12(1):e10681
pubmed: 31793740
Nat Commun. 2019 Jan 3;10(1):38
pubmed: 30604764
Gastroenterology. 2011 May;140(6):1807-16
pubmed: 21530747
PLoS One. 2012;7(12):e51848
pubmed: 23272179
J Clin Invest. 2014 Mar;124(3):1283-95
pubmed: 24487592
Dis Model Mech. 2021 May 1;14(5):
pubmed: 33969420
Agents Actions. 1992;Spec No:C76-8
pubmed: 1442339
Immunobiology. 2010 Mar;215(3):242-9
pubmed: 19457576
Cancer Cell. 2009 Sep 8;16(3):183-94
pubmed: 19732719
Curr Protoc Microbiol. 2006 Jan;Chapter 13:Unit 13A.1
pubmed: 18770577
Gastroenterol Res Pract. 2019 Nov 03;2019:5363261
pubmed: 31781191
J Immunol Methods. 1994 Sep 14;174(1-2):83-93
pubmed: 8083541
Cell. 2019 Jul 25;178(3):714-730.e22
pubmed: 31348891
Cancer Res. 2002 Dec 1;62(23):7042-9
pubmed: 12460925
Cancer Sci. 2003 Nov;94(11):965-73
pubmed: 14611673
PLoS One. 2013 Nov 11;8(11):e79182
pubmed: 24244446
World J Gastroenterol. 2016 May 28;22(20):4794-801
pubmed: 27239106
J Immunol Methods. 1996 Jun 14;193(1):93-9
pubmed: 8690935
Oncogene. 2012 Mar 15;31(11):1459-67
pubmed: 21822305
Front Immunol. 2019 May 24;10:1084
pubmed: 31178859
J Exp Med. 1995 Nov 1;182(5):1281-90
pubmed: 7595199